Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDTX Cidara Therapeutics	$47.80 -0.2%	$27.71	$10.14 ▼ $56.83	$983.60M	1.14	181,123 shs	412,729 shs
ELVN Enliven Therapeutics	$20.68 +0.2%	$19.58	$13.30 ▼ $30.03	$1.02B	0.83	297,479 shs	272,510 shs
MLYS Mineralys Therapeutics	$14.53 +1.6%	$14.94	$8.24 ▼ $18.38	$947.65M	-0.3	548,250 shs	349,918 shs
PHVS Pharvaris	$18.76 +5.3%	$17.06	$11.51 ▼ $25.50	$972.59M	-2.82	71,304 shs	29,451 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDTX Cidara Therapeutics	0.00%	-3.35%	+98.73%	+190.90%	+297.96%
ELVN Enliven Therapeutics	0.00%	-0.02%	-3.25%	+10.62%	-4.06%
MLYS Mineralys Therapeutics	0.00%	+5.94%	-7.01%	+17.14%	+19.55%
PHVS Pharvaris	0.00%	+10.35%	+16.88%	+31.37%	+10.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership
CDTX Cidara Therapeutics	4.2322 of 5 stars	3.6	2.0	4.6	3.8	1.7
ELVN Enliven Therapeutics	2.5111 of 5 stars	3.5	0.0	0.0	3.2	4.2
MLYS Mineralys Therapeutics	2.1568 of 5 stars	3.4	1.0	0.0	1.4	4.2
PHVS Pharvaris	1.5621 of 5 stars	3.5	1.0	0.0	2.3	0.8

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDTX Cidara Therapeutics	3.11	Buy	$57.14	19.56% Upside
ELVN Enliven Therapeutics	3.00	Buy	$41.20	99.27% Upside
MLYS Mineralys Therapeutics	2.75	Moderate Buy	$32.25	122.03% Upside
PHVS Pharvaris	3.00	Buy	$36.20	92.96% Upside

Current Analyst Ratings Breakdown

Latest CDTX, MLYS, ELVN, and PHVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $48.00
6/30/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$59.00
6/24/2025	CDTX Cidara Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/24/2025	CDTX Cidara Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$35.00 ➝ $75.00
6/24/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$50.00 ➝ $68.00
6/23/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00 ➝ $53.00
6/23/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$36.00 ➝ $54.00
6/23/2025	CDTX Cidara Therapeutics	WBB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$45.00
6/18/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$41.00
6/17/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00
6/16/2025	ELVN Enliven Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $52.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDTX Cidara Therapeutics	$302K	3,191.19	N/A	N/A	$14.92 per share	3.20
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$6.34 per share	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	$5.54 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDTX Cidara Therapeutics	-$169.83M	-$29.47	N/A	N/A	N/A	N/A	-73.04%	-54.28%	8/12/2025 (Estimated)
ELVN Enliven Therapeutics	-$89.02M	-$1.92	N/A	N/A	N/A	N/A	-31.84%	-30.09%	8/12/2025 (Estimated)
MLYS Mineralys Therapeutics	-$177.81M	-$3.73	N/A	N/A	N/A	N/A	-71.15%	-65.71%	8/12/2025 (Estimated)
PHVS Pharvaris	-$145.24M	-$3.01	N/A	N/A	N/A	N/A	-54.02%	-50.36%	8/13/2025 (Estimated)

Latest CDTX, MLYS, ELVN, and PHVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/13/2025	Q1 2025	PHVS Pharvaris	-$0.80	-$0.89	-$0.09	-$0.89	N/A	N/A
5/12/2025	Q1 2025	MLYS Mineralys Therapeutics	-$1.02	-$0.79	+$0.23	-$0.79	N/A	N/A
5/8/2025	Q1 2025	CDTX Cidara Therapeutics	-$5.45	-$1.66	+$3.79	-$1.66	N/A	N/A
4/7/2025	Q4 2024	PHVS Pharvaris	-$0.74	-$0.68	+$0.06	-$0.68	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDTX Cidara Therapeutics	N/A	3.87	3.87
ELVN Enliven Therapeutics	N/A	21.07	21.06
MLYS Mineralys Therapeutics	N/A	26.48	26.48
PHVS Pharvaris	N/A	11.10	11.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDTX Cidara Therapeutics	35.82%
ELVN Enliven Therapeutics	95.08%
MLYS Mineralys Therapeutics	84.46%
PHVS Pharvaris	N/A

Insider Ownership

Company	Insider Ownership
CDTX Cidara Therapeutics	3.89%
ELVN Enliven Therapeutics	25.90%
MLYS Mineralys Therapeutics	25.56%
PHVS Pharvaris	11.84%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDTX Cidara Therapeutics	90	20.16 million	19.38 million	No Data
ELVN Enliven Therapeutics	50	49.07 million	36.36 million	Optionable
MLYS Mineralys Therapeutics	28	65.18 million	48.52 million	Optionable
PHVS Pharvaris	30	52.29 million	46.10 million	Not Optionable

CDTX, MLYS, ELVN, and PHVS Headlines

Recent News About These Companies

Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Rating of "Buy" from Brokerages

July 6 at 4:34 AM | marketbeat.com

Pharvaris (NASDAQ:PHVS) Shares Gap Up - What's Next?

July 3 at 11:48 AM | marketbeat.com

Pharvaris (NASDAQ:PHVS) Trading Down 4.9% - What's Next?

June 27, 2025 | marketbeat.com

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

June 27, 2025 | globenewswire.com

Pharvaris N.V. (9EN.F) stock price, news, quote & history - Yahoo Finance

June 26, 2025 | sg.finance.yahoo.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (BMY) and Pharvaris (PHVS)

June 24, 2025 | theglobeandmail.com

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat ...

June 16, 2025 | gurufocus.com

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat ...

June 16, 2025 | gurufocus.com

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress

June 16, 2025 | globenewswire.com

Pharvaris (NASDAQ:PHVS) Given Average Rating of "Buy" by Brokerages

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Predicts Pharvaris FY2026 Earnings

June 11, 2025 | marketbeat.com

Pharvaris (NASDAQ:PHVS) Now Covered by Analysts at Guggenheim

June 11, 2025 | marketbeat.com

Bank of America Corp DE Increases Stake in Pharvaris (NASDAQ:PHVS)

June 11, 2025 | marketbeat.com

Pharvaris Announces 2025 Annual Shareholders Meeting Amidst Phase 3 Trials

June 10, 2025 | tipranks.com

Pharvaris Announces Annual Meeting of Shareholders

June 10, 2025 | globenewswire.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 14,838 Shares of Pharvaris (NASDAQ:PHVS)

June 10, 2025 | marketbeat.com

What is Leerink Partnrs' Forecast for Pharvaris Q2 Earnings?

June 9, 2025 | marketbeat.com

Pharvaris’s Deucrictibant: Expanding Market Reach in Bradykinin-Mediated Angioedemas with Promising Phase 3 Trials

June 5, 2025 | tipranks.com

Pharvaris reports promising results for deucrictibant in HAE

June 3, 2025 | investing.com

Pharvaris reports promising results for deucrictibant in HAE

June 3, 2025 | investing.com

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in ...

June 2, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
By Nathan Reiff | June 30, 2025
View Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains

CDTX, MLYS, ELVN, and PHVS Company Descriptions

Cidara Therapeutics NASDAQ:CDTX

$47.80 -0.08 (-0.16%)

Closing price 07/3/2025 03:55 PM Eastern

Extended Trading

$48.36 +0.56 (+1.17%)

As of 07/3/2025 04:32 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Enliven Therapeutics NASDAQ:ELVN

$20.68 +0.04 (+0.17%)

Closing price 07/3/2025 01:04 PM Eastern

Extended Trading

$20.68 0.00 (0.00%)

As of 07/3/2025 04:33 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Mineralys Therapeutics NASDAQ:MLYS

$14.52 +0.23 (+1.57%)

Closing price 07/3/2025 03:09 PM Eastern

Extended Trading

$14.52 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Pharvaris NASDAQ:PHVS

$18.76 +0.94 (+5.27%)

As of 07/3/2025 02:23 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time